Market Overview:
Basal insulin is a long-acting insulin that helps to keep blood sugar levels under control between meals and overnight. It is used to treat people with type 1 diabetes and type 2 diabetes. The global basal insulin market is expected to grow at a CAGR of 6.5% during the forecast period 2018-2030. Some of the key factors driving the growth of this market are rising prevalence of diabetes, increasing awareness about benefits of basal insulin, and technological advancements in basal insulin products.
 Industry Outlook.svg)
Product Definition:
Basal insulin is a long-acting form of insulin that helps to keep blood sugar levels under control between meals and overnight. Basal insulin is usually given by injection once or twice a day.
Lantus:
Lantus is a long-acting insulin, which was approved by the U.S. FDA in 2013 for diabetic patients who require an infusion of insulin for maintaining blood glucose levels at or below 7% of the maximum level and have difficulty achieving this with short-acting insulin analogs (IDAS). It is indicated for use in adults with diabetes aged 18 years and above. The product has been observed to reduce hypoglycemia by up to 50%.
Levemir:
Levemir (implants/susbstatin) is a long-acting type of insulin, which was first approved by the U.S. FDA in 2003 for use with the Novo Nordisk system.
Application Insights:
The application segment includes type 1 and type 2 diabetes. Type 1 diabetes, formerly known as juvenile or insulin-dependent diabetes has a high prevalence rate and affects people of all ages. It is characterized by the body¢â‚¬â„¢s inability to produce insulin, leading to high blood sugar levels. The current treatment involves the use of insulin injections along with dietary management training for patients suffering from this disease.
Type 2 diabetes is a growing concern worldwide and considered as a modifiable risk factor for cardiovascular diseases due to its increasing incidence rates over the past few years. This condition results in severe damage to the pancreas resulting in decreased production of insulin by this gland; hence, increased usage of oral hypoglycemic drugs (OHD).
Regional Analysis:
North America dominated the global market in 2017 owing to a rise in the prevalence of type 1 diabetes and an increase in awareness about new products. In addition, favorable government initiatives for product development are expected to drive regional growth over the forecast period. Asia Pacific is expected to be one of the fastest-growing regions due to rising disposable income levels and improving economic conditions especially in developing countries such as China & India. Moreover, increasing healthcare expenditure by governments is also anticipated to fuel industry expansion over the next eight years.
The key players operating in this industry include Novo Nordisk A/S; Sanofi; Takeda Pharmaceutical Co., Ltd.; Shire; Johnson & Johnson Services Inc.; Unilife Corporation; Pfizer Inc.
Growth Factors:
- Increasing prevalence of diabetes: The global prevalence of diabetes is increasing at an alarming rate. This is primarily due to the changing lifestyle and dietary habits of people across the world. As a result, there is an increased demand for basal insulin products to help manage blood sugar levels in patients with diabetes.
- Growing awareness about the benefits of basal insulin: There is a growing awareness among healthcare professionals and patients about the benefits of using basal insulin products for managing blood sugar levels in people with diabetes mellitus type 1 and type 2. This is likely to lead to an increase in demand for these products in the coming years.
- Technological advancements: The Basal Insulin (Long-Acting Insulin) market has witnessed several technological advancements over the past few years, which has helped improve patient compliance rates and treatment outcomes. These advancements are likely to continue in future, resulting in greater adoption of basal insulin therapies by patients worldwide.
Scope Of The Report
Report Attributes
Report Details
Report Title
Basal Insulin (Long-Acting Insulin) Market Research Report
By Type
Lantus, Levemir, Tresiba, Toujeo, Basaglar, Biosimilar Glargines
By Application
Type 1 Diabetes, Type 2 Diabetes
By Companies
Novo Nordisk, Sanofi Aventis, Eli Lilly, Biocon, Julphar, Exir, Sedico, Wockhardt
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
156
Number of Tables & Figures
110
Customization Available
Yes, the report can be customized as per your need.
Global Basal Insulin (Long-Acting Insulin) Market Report Segments:
The global Basal Insulin (Long-Acting Insulin) market is segmented on the basis of:
Types
Lantus, Levemir, Tresiba, Toujeo, Basaglar, Biosimilar Glargines
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Type 1 Diabetes, Type 2 Diabetes
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novo Nordisk
- Sanofi Aventis
- Eli Lilly
- Biocon
- Julphar
- Exir
- Sedico
- Wockhardt
 Market Overview.svg)
Highlights of The Basal Insulin (Long-Acting Insulin) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Lantus
- Levemir
- Tresiba
- Toujeo
- Basaglar
- Biosimilar Glargines
- By Application:
- Type 1 Diabetes
- Type 2 Diabetes
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Basal Insulin (Long-Acting Insulin) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Basal insulin is a long-acting form of insulin that is injected once per day. It helps to maintain blood sugar levels in the normal range by helping to control the amount of glucose that is absorbed from food.
Some of the major companies in the basal insulin (long-acting insulin) market are Novo Nordisk, Sanofi Aventis, Eli Lilly, Biocon, Julphar, Exir, Sedico, Wockhardt.
The basal insulin (long-acting insulin) market is expected to register a CAGR of 6.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Basal Insulin (Long-Acting Insulin) Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Basal Insulin (Long-Acting Insulin) Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Basal Insulin (Long-Acting Insulin) Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Basal Insulin (Long-Acting Insulin) Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Basal Insulin (Long-Acting Insulin) Market Size & Forecast, 2018-2028
4.5.1 Basal Insulin (Long-Acting Insulin) Market Size and Y-o-Y Growth
4.5.2 Basal Insulin (Long-Acting Insulin) Market Absolute $ Opportunity
Chapter 5 Global Basal Insulin (Long-Acting Insulin) Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Basal Insulin (Long-Acting Insulin) Market Size Forecast by Type
5.2.1 Lantus
5.2.2 Levemir
5.2.3 Tresiba
5.2.4 Toujeo
5.2.5 Basaglar
5.2.6 Biosimilar Glargines
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Basal Insulin (Long-Acting Insulin) Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Basal Insulin (Long-Acting Insulin) Market Size Forecast by Applications
6.2.1 Type 1 Diabetes
6.2.2 Type 2 Diabetes
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Basal Insulin (Long-Acting Insulin) Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Basal Insulin (Long-Acting Insulin) Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Basal Insulin (Long-Acting Insulin) Analysis and Forecast
9.1 Introduction
9.2 North America Basal Insulin (Long-Acting Insulin) Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Basal Insulin (Long-Acting Insulin) Market Size Forecast by Type
9.6.1 Lantus
9.6.2 Levemir
9.6.3 Tresiba
9.6.4 Toujeo
9.6.5 Basaglar
9.6.6 Biosimilar Glargines
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Basal Insulin (Long-Acting Insulin) Market Size Forecast by Applications
9.10.1 Type 1 Diabetes
9.10.2 Type 2 Diabetes
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Basal Insulin (Long-Acting Insulin) Analysis and Forecast
10.1 Introduction
10.2 Europe Basal Insulin (Long-Acting Insulin) Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Basal Insulin (Long-Acting Insulin) Market Size Forecast by Type
10.6.1 Lantus
10.6.2 Levemir
10.6.3 Tresiba
10.6.4 Toujeo
10.6.5 Basaglar
10.6.6 Biosimilar Glargines
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Basal Insulin (Long-Acting Insulin) Market Size Forecast by Applications
10.10.1 Type 1 Diabetes
10.10.2 Type 2 Diabetes
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Basal Insulin (Long-Acting Insulin) Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Basal Insulin (Long-Acting Insulin) Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Basal Insulin (Long-Acting Insulin) Market Size Forecast by Type
11.6.1 Lantus
11.6.2 Levemir
11.6.3 Tresiba
11.6.4 Toujeo
11.6.5 Basaglar
11.6.6 Biosimilar Glargines
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Basal Insulin (Long-Acting Insulin) Market Size Forecast by Applications
11.10.1 Type 1 Diabetes
11.10.2 Type 2 Diabetes
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Basal Insulin (Long-Acting Insulin) Analysis and Forecast
12.1 Introduction
12.2 Latin America Basal Insulin (Long-Acting Insulin) Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Basal Insulin (Long-Acting Insulin) Market Size Forecast by Type
12.6.1 Lantus
12.6.2 Levemir
12.6.3 Tresiba
12.6.4 Toujeo
12.6.5 Basaglar
12.6.6 Biosimilar Glargines
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Basal Insulin (Long-Acting Insulin) Market Size Forecast by Applications
12.10.1 Type 1 Diabetes
12.10.2 Type 2 Diabetes
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Basal Insulin (Long-Acting Insulin) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Basal Insulin (Long-Acting Insulin) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Basal Insulin (Long-Acting Insulin) Market Size Forecast by Type
13.6.1 Lantus
13.6.2 Levemir
13.6.3 Tresiba
13.6.4 Toujeo
13.6.5 Basaglar
13.6.6 Biosimilar Glargines
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Basal Insulin (Long-Acting Insulin) Market Size Forecast by Applications
13.10.1 Type 1 Diabetes
13.10.2 Type 2 Diabetes
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Basal Insulin (Long-Acting Insulin) Market: Competitive Dashboard
14.2 Global Basal Insulin (Long-Acting Insulin) Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Novo Nordisk
14.3.2 Sanofi Aventis
14.3.3 Eli Lilly
14.3.4 Biocon
14.3.5 Julphar
14.3.6 Exir
14.3.7 Sedico
14.3.8 Wockhardt
